Does a Wound-Healing gel raise cancer risk? new study aims to find out
NCT ID NCT06423573
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 580 people with dystrophic or junctional epidermolysis bullosa (EB) for up to 5 years. Researchers want to see if using Filsuvez, a birch bark extract gel that helps heal blisters, changes the risk of developing skin cancer. Participants receive standard care, with or without Filsuvez, and are monitored for new skin malignancies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Filsuvez (birch bark extract gel)
What this could lead to
If it shows that Filsuvez does not increase skin cancer risk, it would support its safe long-term use for wound healing in epidermolysis bullosa.
What could go wrong
This is an observational study, not a controlled trial, so it can only suggest links, not prove cause and effect. Results may take years and could be inconclusive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA, DYSTROPHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Toulouse, Hôpital Larrey
RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Guy's and St Thomas' NHS Foundation Trust
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Clinic, Barcelona
RECRUITINGBarcelona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital San Juan de Dios (Barcelona)
RECRUITINGBarcelona, Spain
Contact Email: •••••@•••••
Contact
-
Hospital of Skin and Venereal Diseases of Thessaloniki
RECRUITINGThessaloniki, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact